AU2016238253B2 - Digital analysis of circulating tumor cells in blood samples - Google Patents

Digital analysis of circulating tumor cells in blood samples Download PDF

Info

Publication number
AU2016238253B2
AU2016238253B2 AU2016238253A AU2016238253A AU2016238253B2 AU 2016238253 B2 AU2016238253 B2 AU 2016238253B2 AU 2016238253 A AU2016238253 A AU 2016238253A AU 2016238253 A AU2016238253 A AU 2016238253A AU 2016238253 B2 AU2016238253 B2 AU 2016238253B2
Authority
AU
Australia
Prior art keywords
primer
seq
cancer
ctcs
cdna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016238253A
Other languages
English (en)
Other versions
AU2016238253A1 (en
Inventor
Daniel A. Haber
Xin Hong
Sarah JAVAID
Ravi Kapur
Shyamala Maheswaran
David Tomoaki MIYAMOTO
Tanya TODOROVA
Mehmet Toner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of AU2016238253A1 publication Critical patent/AU2016238253A1/en
Application granted granted Critical
Publication of AU2016238253B2 publication Critical patent/AU2016238253B2/en
Priority to AU2022231734A priority Critical patent/AU2022231734A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/159—Microreactors, e.g. emulsion PCR or sequencing, droplet PCR, microcapsules, i.e. non-liquid containers with a range of different permeability's for different reaction components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/60—Detection means characterised by use of a special device
    • C12Q2565/629—Detection means characterised by use of a special device being a microfluidic device
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2016238253A 2015-03-25 2016-03-25 Digital analysis of circulating tumor cells in blood samples Active AU2016238253B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022231734A AU2022231734A1 (en) 2015-03-25 2022-09-15 Digital analysis of circulating tumor cells in blood samples

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562137891P 2015-03-25 2015-03-25
US62/137,891 2015-03-25
US201562219339P 2015-09-16 2015-09-16
US62/219,339 2015-09-16
US201562253619P 2015-11-10 2015-11-10
US62/253,619 2015-11-10
PCT/US2016/024367 WO2016154600A1 (en) 2015-03-25 2016-03-25 Digital analysis of circulating tumor cells in blood samples

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022231734A Division AU2022231734A1 (en) 2015-03-25 2022-09-15 Digital analysis of circulating tumor cells in blood samples

Publications (2)

Publication Number Publication Date
AU2016238253A1 AU2016238253A1 (en) 2017-10-19
AU2016238253B2 true AU2016238253B2 (en) 2022-06-16

Family

ID=56977798

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016238253A Active AU2016238253B2 (en) 2015-03-25 2016-03-25 Digital analysis of circulating tumor cells in blood samples
AU2022231734A Abandoned AU2022231734A1 (en) 2015-03-25 2022-09-15 Digital analysis of circulating tumor cells in blood samples

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022231734A Abandoned AU2022231734A1 (en) 2015-03-25 2022-09-15 Digital analysis of circulating tumor cells in blood samples

Country Status (10)

Country Link
US (3) US20180057889A1 (enExample)
EP (1) EP3274476B1 (enExample)
JP (2) JP7144934B2 (enExample)
KR (1) KR102502087B1 (enExample)
CN (1) CN107614698A (enExample)
AU (2) AU2016238253B2 (enExample)
CA (1) CA2980562A1 (enExample)
ES (1) ES2954456T3 (enExample)
IL (1) IL254639B (enExample)
WO (1) WO2016154600A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3544015B1 (en) 2012-02-03 2024-10-23 California Institute of Technology Signal encoding and decoding in multiplexed biochemical assays
AU2016238253B2 (en) 2015-03-25 2022-06-16 The General Hospital Corporation Digital analysis of circulating tumor cells in blood samples
WO2018081625A2 (en) * 2016-10-27 2018-05-03 The General Hospital Corporation Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers
US20180252722A1 (en) * 2017-03-05 2018-09-06 Yan Wang PCR-based Method for Counting Circulating Tumor Cells
JP2021502098A (ja) * 2017-11-09 2021-01-28 ビオミレニア ソシエテ パ アクシオンス シンプリフィエ 微生物選択システム
WO2019165242A1 (en) * 2018-02-23 2019-08-29 Paraskevi Giannakakou Assay for detection of androgen receptor variants
CN108535145A (zh) * 2018-03-09 2018-09-14 深圳市瑞图生物技术有限公司 快速检测外周血液中网织红细胞数量的方法及装置
CN112424377A (zh) 2018-04-17 2021-02-26 克罗玛科德公司 用于多重分析的方法和系统
CN110456034B (zh) * 2018-05-07 2022-07-22 上海市第十人民医院 一种循环肿瘤细胞的检测方法
EP3814775A4 (en) 2018-06-29 2021-09-01 The General Hospital Corporation ISOLATION AND ANALYSIS OF CELLS AND RARE PARTICLES DERIVED FROM THE BRAIN
US12203129B2 (en) * 2018-07-03 2025-01-21 ChromaCode, Inc. Formulations and signal encoding and decoding methods for massively multiplexed biochemical assays
JP2022500029A (ja) * 2018-09-11 2022-01-04 ザ ジェネラル ホスピタル コーポレイション 肝臓疾患を検出する方法
KR102380529B1 (ko) * 2020-04-29 2022-03-31 인제대학교 산학협력단 전이성 전립선 암의 진단 및 예후 예측을 위한 혈중종양세포 기반 바이오 마커 조성물
CN112662774A (zh) * 2021-01-12 2021-04-16 南方医科大学南方医院 一种肝癌循环肿瘤细胞标志物及其应用
CN114395622A (zh) * 2021-12-13 2022-04-26 深圳先进技术研究院 一种利用数字pcr检测循环肿瘤细胞egfr基因突变的方法及其应用
DE102022211089A1 (de) * 2022-10-19 2024-04-25 Robert Bosch Gesellschaft mit beschränkter Haftung Kombinierte Zellspezifische Markierung und Anreicherung von Biomarkern

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009051734A1 (en) * 2007-10-17 2009-04-23 The General Hospital Corporation Microchip-based devices for capturing circulating tumor cells and methods of their use
US20110059556A1 (en) * 2009-09-04 2011-03-10 The Research Foundation Of State University Of New York Rapid and Continuous Analyte Processing in Droplet Microfluidic Devices
US20110166030A1 (en) * 2009-09-30 2011-07-07 Yixin Wang Prediction of response to docetaxel therapy based on the presence of TMPRSSG2:ERG fusion in circulating tumor cells
WO2011112903A2 (en) * 2010-03-11 2011-09-15 Board Of Regents, The University Of Texas System Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of breast cancer patients
US20120015835A1 (en) * 2005-07-29 2012-01-19 Martin Fuchs Devices and Methods for Enrichment and Alteration of Circulating Tumor Cells and Other Particles
WO2014028378A2 (en) * 2012-08-13 2014-02-20 The Regents Of The University Of California Methods and systems for detecting biological components

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8535A (en) 1851-11-18 Stove-geate
US889A (en) 1838-08-20 Mode of constructing metal bench-vises
DE29623597U1 (de) 1996-11-08 1999-01-07 Eppendorf - Netheler - Hinz Gmbh, 22339 Hamburg Temperierblock mit Temperiereinrichtungen
US20080050393A1 (en) 1998-12-03 2008-02-28 Tang Y Tom Novel nucleic acids and polypeptides
CA2311201A1 (en) * 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins
WO2002012328A2 (en) * 2000-08-03 2002-02-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
JP2004537261A (ja) 2000-12-08 2004-12-16 イプソゲン 候補遺伝子のアレイを用いた原発性乳がんの遺伝子発現プロファイリング
WO2002092854A2 (en) 2001-05-16 2002-11-21 Novartis Ag Genes expressed in breast cancer as prognostic and therapeutic targets
US20030073623A1 (en) 2001-07-30 2003-04-17 Drmanac Radoje T. Novel nucleic acid sequences obtained from various cDNA libraries
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
WO2006121991A2 (en) 2005-05-06 2006-11-16 Diadexus, Inc. Compositions and methods for detection, prognosis and treatment of breast cancer
US20090275486A1 (en) * 2006-05-16 2009-11-05 Nurith Kurn Nucleic acid separation and purification method based on reversible charge interactions
US8372584B2 (en) * 2006-06-14 2013-02-12 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US9068181B2 (en) 2008-05-23 2015-06-30 The General Hospital Corporation Microfluidic droplet encapsulation
US20120252015A1 (en) * 2011-02-18 2012-10-04 Bio-Rad Laboratories Methods and compositions for detecting genetic material
US8535889B2 (en) 2010-02-12 2013-09-17 Raindance Technologies, Inc. Digital analyte analysis
AU2015268617A1 (en) 2010-03-31 2016-01-07 Sividon Diagnostics Gmbh Method for breast cancer recurrence prediction under endocrine treatment
JP5940517B2 (ja) 2010-03-31 2016-06-29 ジヴィドン ダイアグノスティックス ゲゼルシャフト ミット ベシュレンクテル ハフツング 内分泌治療下における乳癌再発を予測するための方法
US9650629B2 (en) * 2010-07-07 2017-05-16 Roche Molecular Systems, Inc. Clonal pre-amplification in emulsion
EP2606353A4 (en) 2010-08-18 2014-10-15 Caris Life Sciences Luxembourg Holdings CIRCULATING BIOMARKERS FOR DISEASES
WO2012115885A1 (en) 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
WO2012135397A2 (en) 2011-03-29 2012-10-04 Lisanti Michael P Lactate-and ketones-induced gene signatures and use the same for diagnosing disease and predicting clinical outcome
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
JP6247218B2 (ja) * 2011-10-24 2017-12-13 ザ ジェネラル ホスピタル コーポレイション 癌のバイオマーカー
US9766244B2 (en) 2012-07-02 2017-09-19 The General Hospital Corporation Diagnosis and monitoring treatment of prostate cancer
EP2895625B1 (en) 2012-09-14 2018-04-18 Memorial Sloan-Kettering Cancer Center Genes associated with dasatinib sensitivity
WO2014047285A1 (en) 2012-09-19 2014-03-27 Paraskevi Giannakakou Identifying taxane sensitivity in prostate cancer patients
WO2014075067A1 (en) 2012-11-12 2014-05-15 Nanostring Technologies, Inc. Methods to predict breast cancer outcome
US20140303005A1 (en) 2013-04-05 2014-10-09 Raindance Technologies, Inc. Rare cell analysis after negative selection
KR20160058774A (ko) 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
WO2015058206A1 (en) 2013-10-18 2015-04-23 The General Hosptial Corporation Microfluidic sorting using high gradient magnetic fields
RU2016137150A (ru) 2014-03-13 2018-04-18 Ф. Хоффманн-Ля Рош Аг Способы и композиции для модулирования мутантов эстрогеновых рецепторов
WO2015177184A1 (en) 2014-05-21 2015-11-26 F. Hoffmann-La Roche Ag Methods of treating pr-positive, luminal a breast cancer with pi3k inhibitor, pictilisib
CN107003300B (zh) 2014-12-12 2020-02-07 凯尔科迪股份有限公司 测量erbb信号传导通路活性以诊断和治疗癌症患者的方法
ES2719206T3 (es) 2015-02-20 2019-07-09 Comelz Spa Procedimiento para cortar pieles naturales
RS62972B1 (sr) 2015-03-12 2022-03-31 Janssen Pharmaceutica Nv Mrnk markeri na bazi pune krvi za predviđivanje raka prostate i metode otkrivanja istog
AU2016238253B2 (en) 2015-03-25 2022-06-16 The General Hospital Corporation Digital analysis of circulating tumor cells in blood samples
WO2018081625A2 (en) 2016-10-27 2018-05-03 The General Hospital Corporation Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120015835A1 (en) * 2005-07-29 2012-01-19 Martin Fuchs Devices and Methods for Enrichment and Alteration of Circulating Tumor Cells and Other Particles
WO2009051734A1 (en) * 2007-10-17 2009-04-23 The General Hospital Corporation Microchip-based devices for capturing circulating tumor cells and methods of their use
US20110059556A1 (en) * 2009-09-04 2011-03-10 The Research Foundation Of State University Of New York Rapid and Continuous Analyte Processing in Droplet Microfluidic Devices
US20110166030A1 (en) * 2009-09-30 2011-07-07 Yixin Wang Prediction of response to docetaxel therapy based on the presence of TMPRSSG2:ERG fusion in circulating tumor cells
WO2011112903A2 (en) * 2010-03-11 2011-09-15 Board Of Regents, The University Of Texas System Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of breast cancer patients
WO2014028378A2 (en) * 2012-08-13 2014-02-20 The Regents Of The University Of California Methods and systems for detecting biological components

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HAYES, D.F. ET AL. "Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival", Clin Cancer Res, 2006, 12(14), pp 4218 - 4224 *
KIM, M.J. ET AL., "Identification of novel markers that outperform EpCAM in quantifying circulating tumor cells", Cell Oncol, 2014, vol 37, pp 235 - 243 *
RAMSKOLD, D., ET AL., "Full-Length mRNA-Seq from single cell levels of RNA and individual circulating tumor cells", NAT BIOTECHNOL., 2012, 30(8), pp 777-782 *
STOTT SHANNON L ET AL, "Isolation and Characterization of Circulating Tumor Cells from Patients with Localized and Metastatic Prostate Cancer", SCIENCE TRANSLATIONAL MEDICINE, 2010, vol. 2, no. 25, pp 111 - 120 *

Also Published As

Publication number Publication date
US20180057889A1 (en) 2018-03-01
EP3274476A4 (en) 2018-08-29
JP2018513679A (ja) 2018-05-31
US20210189501A1 (en) 2021-06-24
WO2016154600A1 (en) 2016-09-29
CA2980562A1 (en) 2016-09-29
EP3274476A1 (en) 2018-01-31
JP2021087428A (ja) 2021-06-10
IL254639A0 (en) 2017-11-30
KR102502087B1 (ko) 2023-02-20
US11898209B2 (en) 2024-02-13
IL254639B (en) 2021-10-31
EP3274476B1 (en) 2023-06-07
CN107614698A (zh) 2018-01-19
JP7203128B2 (ja) 2023-01-12
AU2016238253A1 (en) 2017-10-19
HK1249553A1 (en) 2018-11-02
KR20170131516A (ko) 2017-11-29
AU2022231734A1 (en) 2022-11-10
US20240132969A1 (en) 2024-04-25
ES2954456T3 (es) 2023-11-22
JP7144934B2 (ja) 2022-09-30

Similar Documents

Publication Publication Date Title
US20240132969A1 (en) Digital Analysis of Circulating Tumor Cells in Blood Samples
JP7441907B2 (ja) 特定のがんに対するがん療法についてその有効性を判定するための血液サンプルのデジタル分析
Matuła et al. Single‐cell analysis using droplet microfluidics
Hickman et al. Analysis of the microglial sensome
Leonaviciene et al. RNA cytometry of single-cells using semi-permeable microcapsules
CN111819291A (zh) 用于体液鉴定的方法
KR20250080858A (ko) 바이오마커 식별 방법 및 제품
US20180252722A1 (en) PCR-based Method for Counting Circulating Tumor Cells
CN110747275B (zh) 肿瘤细胞标记分子及其应用
HK1249553B (en) Digital analysis of circulating tumor cells in blood samples
Zhou et al. Protocol to dissociate and isolate wide-diversity single cells by density gradient centrifugation from human hepatoblastoma tissue
US12286622B2 (en) Genomics-based identification and characterization of rare cell types
Jepson Single-cell MicroRNA Sequencing of Circulating Tumour Cells: A New Tool for Monitoring Prostate Cancer
Swennenhuis Unmasking circulating tumor cells
RU2626603C2 (ru) Способ определения риска возникновения рецидива онкологических заболеваний молочной железы
Škereňová Individualization of the treatment of prostate cancer patients based on the immunocytochemical detection of circulating tumor cells

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)